Shlomo te vas de TEVA...?

Depués de profundas (y serias) meditaciones la decisión está tomada. Shlomo Yanai deja TEVA a partir de mayo. Su puesto será ocupado por Jeremy Levin (58a) médico sudafricano que fué senior executive en Bristol-Myers Squibb Co.
En PHARMACOSERÍAS perdemos uno de nuestros "habitués"

Teva Pharmaceutical Industries Ltd.,the Jerusalem drugmaker, said President and Chief Executive Shlomo Yanai would step down in May, after more than five years at the helm. A late Sunday statement says, without elaboration, that Yanai plans "to move on to a new phase in his career." Teva said that as part of a succession plan and after a search, the board named Jeremy Levin, 58, a South-Africa-born physician and former senior executive at Bristol-Myers Squibb Co.,to succeed Yanai. Yanai joined Teva in March 2007 from the agrichemicals firm Makhteshim-Agan Industries Ltd., where he'd been president and CEO. If Teva hits its targets this year, it will post revenue around $22 billion; in 2006, the year before Yanai joined, Teva's top line showed around $8.4 billion. Yanai diversified the company's product line from largely generics and widened its geographic presence, the company said. (Más)

Ver:

Why Teva Hired A Bristol-Myers Exec As Its CEO

Teva getting its first non-Israeli CEO as Shlomo Yanai resigns

Departure of Bristol’s Deal Strategist to Teva Leaves a Hole